Отчет об анализе размера, доли и тенденций мирового рынка противосудорожных препаратов – обзор отрасли и прогноз до 2031 года

Анализ рынка противосудорожных препаратов

Мировой рынок противосудорожных препаратов переживает значительный рост, обусловленный растущей распространенностью эпилепсии и других неврологических расстройств. Такие факторы, как достижения в области лекарственных формул, растущая осведомленность об эпилепсии и спрос на эффективные варианты лечения, способствуют расширению рынка. Более того, растущее гериатрическое население, склонное к судорожным расстройствам, еще больше усиливает потенциал рынка. Северная Америка занимает существенную долю, что объясняется высокими расходами на здравоохранение и активной исследовательской деятельностью. Напротив, Азиатско-Тихоокеанский регион становится ключевым игроком благодаря улучшению инфраструктуры здравоохранения и увеличению численности пациентов. Рынок характеризуется конкурентной средой, в которой многочисленные фармацевтические компании сосредоточены на инновациях и стратегических партнерствах для улучшения своих продуктовых предложений.

Размер рынка противосудорожных препаратов

Объем мирового рынка противосудорожных препаратов в 2023 году оценивался в 7,08 млрд долларов США, а к 2031 году, по прогнозам, он достигнет 10,39 млрд долларов США, при среднегодовом темпе роста 4,90% в прогнозируемый период с 2024 по 2031 год. Помимо информации о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, подготовленные Data Bridge Market Research, также включают в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ линейки препаратов, анализ цен и нормативно-правовую базу.

Тенденции рынка противосудорожных препаратов

« Растущее развитие персонализированной медицины»

На рынке противосудорожных препаратов наблюдается заметная тенденция к развитию персонализированной медицины, которая подбирает лечение под индивидуальные профили пациентов. Такой подход повышает эффективность и минимизирует побочные эффекты, учитывая уникальные реакции пациентов на различные противосудорожные препараты. Например, генетическое тестирование может помочь определить, какие лекарства, такие как ламотриджин или леветирацетам, скорее всего, будут наиболее эффективны для конкретных пациентов. Эта тенденция улучшает результаты лечения пациентов и стимулирует рост рынка, поскольку поставщики медицинских услуг все чаще перенимают методы точной медицины. В результате фармацевтические компании инвестируют в исследования для разработки целевых методов лечения, что еще больше меняет ландшафт лечения эпилепсии и формирует будущее рынка противосудорожных препаратов.

Область применения отчета и сегментация рынка противосудорожных препаратов     

Anticonvulsants Market Definition

Anticonvulsants are medications primarily used to prevent or reduce the frequency of seizures in individuals with epilepsy and other seizure disorders. They work by stabilizing electrical activity in the brain, thereby minimizing the occurrence of seizures. These drugs can also be prescribed for other conditions, such as bipolar disorder and neuropathic pain. Common instances include carbamazepine, phenytoin, and valproate. The effectiveness and side effects can vary significantly among patients, necessitating careful selection and monitoring by healthcare providers.

Anticonvulsants Market Dynamics

Drivers

• Increasing Prevalence of Epilepsy

The increasing prevalence of epilepsy significantly drives demand for anticonvulsant medications, with the World Health Organization estimating that around fifty million people worldwide are affected by this neurological disorder. In recent years, the incidence of epilepsy has been reported to be approximately 5-10 cases per 1,000 people, highlighting a growing need for effective treatment options. Moreover, advancements in diagnostic techniques and increased awareness of seizure disorders have led to better identification of affected individuals, allowing more patients to seek timely treatment. This rising awareness and subsequent demand for effective anticonvulsant medications create a significant market driver as healthcare providers strive to manage this chronic condition effectively.

• Increase in Neurological Disorders

The increase in neurological disorders significantly contributes to the growing demand for anticonvulsants, as conditions such Alzheimer’s disease and traumatic brain injuries often lead to seizures. According to the Alzheimer's Association, over 6 million Americans aged 65 and older are living with Alzheimer's disease, a number expected to rise as the population ages. Additionally, the Centers for Disease Control and Prevention (CDC) reports that traumatic brain injuries affect over 2 million people annually in the U.S., with a substantial proportion experiencing seizures as a consequence. These statistics illustrate the correlation between rising neurological disorders and the need for effective anticonvulsant therapies. As healthcare providers aim to manage the complexities associated with these conditions, the demand for anticonvulsants is expected to increase, positioning this factor as a critical market driver.

Opportunities

• Increasing Advancements in Drug Development

Advancements in drug development have significantly influenced the anticonvulsant market by introducing newer medications with enhanced efficacy and safety profiles, presenting substantial market opportunities. For instance, medications such as Lacosamide and Perampanel have emerged in recent years, providing alternatives for patients who do not respond well to traditional treatments. Lacosamide, approved in the U.S. in 2008, has shown effectiveness in treating partial-onset seizures and has a favorable safety profile, making it a preferred choice for many patients. Furthermore, innovations in drug formulation and delivery methods, such as extended-release formulations and personalized medicine approaches, allow for better patient adherence and optimized therapeutic outcomes. These continuous developments highlight the potential for growth in the anticonvulsant market as pharmaceutical companies invest in research and innovation to meet the evolving needs of patients.

• Growing Awareness and Improved Diagnosis

Growing awareness and improved diagnosis of neurological disorders have significantly expanded the patient population in need of anticonvulsant therapies, creating a valuable market opportunity. Initiatives such as public awareness campaigns and educational programs for healthcare providers have led to increased recognition of symptoms associated with epilepsy and other seizure disorders. For instance, the Epilepsy Foundation's "Seize the Awareness" campaign aims to educate both the public and medical professionals about seizure recognition and response, contributing to more timely diagnoses. This heightened awareness facilitates early intervention and drives demand for effective anticonvulsant treatments, providing pharmaceutical companies with the opportunity to cater to a growing market of newly diagnosed patients.

Restraints/Challenges

• Adverse Effects and Side Effects

Adverse effects and side effects associated with anticonvulsant medications pose significant challenges to patient compliance, often leading to non-adherence to treatment regimens. Common side effects include dizziness, fatigue, and cognitive impairment, which can deter patients from continuing their prescribed therapies. For instance, medications such as Carbamazepine and Lamotrigine are effective in managing seizures but can cause drowsiness and cognitive dulling, leading patients to skip doses or abandon treatment altogether. Furthermore, long-term safety concerns related to these medications, such as potential organ damage or increased risk of suicidal thoughts, can create apprehension among both patients and healthcare providers. This hesitance to utilize certain anticonvulsants due to fear of long-term consequences affects individual patient outcomes and presents a broader market challenge, as it limits the adoption of potentially effective therapies in clinical practice.

• High Treatment Costs Associated Novel Therapies

High treatment costs associated with certain anticonvulsants, particularly novel therapies, present a significant barrier to access for patients, especially in low- and middle-income countries. For instance, newer medications such as Brivaracetam and Lacosamide can be significantly more expensive than traditional anticonvulsants, making them unaffordable for many patients who rely on these treatments for seizure management. Additionally, inconsistent reimbursement policies across various regions exacerbate this issue, as some countries may not cover the costs of these newer medications under their national health insurance programs, limiting access for those who need them most. In regions where reimbursement is lacking or varies widely, patients may be forced to choose less effective, older therapies due to financial constraints, which impacts individual health outcomes and stifles overall market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Anticonvulsants Market Scope

The market is segmented on the basis of drug class, dosage, route of administration, application, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Pyrimidinediones
• Benzodiazepines
• Fructose derivatives
• Aromatic allylic alcohols
• Valproylamides
• Carboxamides
• Bromides
• Carbamates
• Aldehydes
• Sulfonamides
• Pyrrolidines
• Triazines
• Fatty acids
• Propionates
• Oxazolidinediones
• Hydantoins
• Barbiturates
• Others

Dosage

• Tablet
• Capsule
• Liquid
• Rectal Gel
• Cream
• Others

Route of Administration

• Topical
• Enteral
• Parenteral

Application

• Migraine
• Epilepsy
• Neuropathic pain
• Anxiety
• Fibromyalgia
• Bipolar Disorder
• Borderline Personality Disorder

End Users

• Clinic
• Hospital
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Anticonvulsants Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, drug class, dosage, route of administration, application, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is anticipated to lead the global Anticonvulsants market, primarily driven by significant investments in the healthcare sector that are projected to stimulate market expansion. Within this region, the United States is expected to take the lead, largely due to its rapid technological advancements in healthcare solutions and innovative treatment options. Additionally, the growing emphasis on early disease detection and personalized medicine in the U.S. further enhances the demand for Anticonvulsants, contributing to the region's dominance in this market.

The Asia-Pacific region is projected to experience significant growth from 2024 to 2031, largely fueled by the availability of azithromycin in both generic and branded forms, making it more accessible to patients. The rapid advancements in the biopharmaceutical sector contribute to the development of innovative therapies, further driving market expansion. Increased research and development activities in the region are fostering a dynamic environment for drug discovery and improvement. Additionally, ongoing developments in the healthcare sector, along with strong government support and initiatives aimed at enhancing healthcare access and affordability, are set to bolster the overall growth of the anticonvulsants market in Asia-Pacific.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Anticonvulsants Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Anticonvulsants Market Leaders Operating in the Market Are:

• Novartis AG (Switzerland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• Johnson & Johnson Private Limited (U.S.)
• Abbott (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bausch Health Companies Inc. (U.S.)
• UCB S.A. (Belgium)
• Sunovion Pharmaceuticals Inc. (U.S.)
• GW Pharmaceuticals plc (U.K.)
• AstraZeneca (U.K.)
• GSK plc (U.K.)
• H. Lundbeck A/S (Denmark)
• Takeda Pharmaceutical Company Limited (Japan)
• Sumitomo Dainippon Pharma Co., Ltd (Japan)
• Biocon (India)
• Merck KGaA (Germany)
• Cadila (India)
• Eisai Co., Ltd (Japan)
• Cipla (India)
• Glenmark Pharmaceuticals Limited (India)
• Mankind Pharma (India)
• Novo Nordisk A/S (Denmark)
• Otsuka America Pharmaceutical, Inc (Japan)
• Wockhardt (India)

Latest Developments in Anticonvulsants Market

• In December 2022, Eisai Co., Ltd. announced an agreement to transfer the U.S. commercial rights for the antiepileptic drug (AED) Fycompa to Catalyst Pharmaceuticals, Inc., granting Catalyst an exclusive negotiation period for a potential asset within Eisai’s epilepsy pipeline
• В августе 2022 года UCB SA заключила три всеобъемлющих соглашения с детской больницей Bonheur, организацией Wisconsin Health Information Organization (WHIO) и Йельским университетом. Целью этих партнерств является более глубокое изучение проблем, с которыми сталкиваются пациенты с кластерными приступами, и повышение осведомленности об этом состоянии
• В феврале 2022 года компания Biohaven Pharmaceutical Holding Company Ltd. завершила сделку по приобретению активаторов каналов Kv7 у Channel Biosciences, LLC, нацеленных на такие показания, как эпилепсия, болевые расстройства и аффективные расстройства.
• В августе 2021 года компания UCB SA получила одобрение Управления по контролю за продуктами и лекарствами США (FDA) на расширенное применение препарата BRIVIACT (бриварацетам) в форме таблеток, инъекций и перорального раствора, что позволяет лечить пациентов в возрасте от одного месяца с парциальными припадками.
• В августе 2021 года Управление по конкуренции и рынкам Великобритании (CMA) оштрафовало компании Pfizer Inc. и Flynn Pharma на 84 миллиона долларов США за взимание с Национальной службы здравоохранения (NHS) завышенной платы за широко используемый препарат от эпилепсии.

SKU-66107